Core Viewpoint - The company reported a significant increase in revenue and a substantial reduction in losses, indicating improved operational efficiency and market positioning in the neuro-interventional medical device sector [1][2]. Financial Performance - The company achieved revenue of RMB 278 million for the fiscal year ending December 31, 2024, representing a year-on-year increase of 19.6% [1]. - Research and development costs amounted to RMB 58.94 million, a decrease of 52.4% compared to the previous year [1]. - The loss attributable to the parent company was RMB 13.62 million, a reduction of 85.51% year-on-year, with a loss per share of RMB 0.36 [1]. - The pre-tax loss narrowed significantly to RMB 12 million, down 88.3% year-on-year, despite a decline in gross margin due to bulk procurement pricing and market competition [1]. Operational Efficiency - The company successfully reduced the expense ratio for sales, distribution, and administrative expenses to 49.6%, down from 66.2% in 2023, reflecting effective cost control and efficiency measures [1]. - The sales volume of acute ischemic stroke treatment devices increased by 45.5%, while revenues from hemorrhagic stroke treatment devices and other interventional devices grew by 104.2% and 109.4%, respectively [1]. Product Development and Market Expansion - The company is focused on upgrading its neuro-interventional business and differentiating its treatment devices to adapt to rapidly changing market conditions [1]. - Research and development efforts are directed towards diverse neuro-interventional treatment devices, with plans to launch at least two major devices in the next 24 months, including self-expanding drug-eluting stents and carotid stents [2]. - The company has received NMPA approval for its intracranial aneurysm embolization assist stent and flow diversion device, which have begun sales [2]. - The company has obtained CE or FDA certifications for several products in overseas markets and is currently conducting over 40 product registrations in 10 countries or regions to expand sales channels [2].

Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 董事會提名委員會工作細則 第一章 總則 第一條 為規範上海心瑋醫療科技股份有限公司（以下簡稱「公司」）董事及高級 管理人員的產生，優化董事會組成，完善公司治理結構，根據《中華人民共和 國公司法》（以下簡稱「《公司法》」）等相關法律、法規、規範性文件、《上海心瑋 醫療科技股份有限公司章程》（以下簡稱「《公司章程》」）和《香港聯合交易所有 限公司證券上市規則》（以下簡稱「《上市規則》」）及中華人民共和國香港特別行 政區其他適用的法律、法規及有關規定，公司特設立董事會提名委員會，並結 合公司實際，制定本《上海心瑋醫療科技股份有限公司董事會提名委員會工作 細則》（以下簡稱「本細則」）。 第二條 董事會提名委員會是董事會按照股東大會決議設立的專門工作機構， 主要職責是擬定公司董事（包括獨立非執行董事）、總經理及其他高級管理人 員的選任程序和標準 ...

執行董事 王國輝先生 （董事長） 張坤女士 韋家威先生 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 董事名單及其角色與職能 本公司董事會（「董事會」）成員載列如下。 非執行董事 丁魁先生 陳少雄先生 陳剛先生 獨立非執行董事 郭少牧先生 馮向前先生 龔平先生 董事會下轄四個委員會。下表列示董事會委員會的組成： | | 委員會 | 審計委員會 | 薪酬委員會 | 提名委員會 | 戰略委員會 | | --- | --- | --- | --- | --- | --- | | 董事 | | | | | | | 王國輝 | | | M | | C | | 張坤 | | | | M | M | | 韋家威 | | | | | | | 丁魁 | | M | | | M | | 陳少雄 | | | | | | | 陳剛 | | | | | M | | 郭少牧 | | | C | M | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） (I)提名委員會組成變動； (II)僱員代表監事變動； 及 (III)執行董事職責變動 提名委員會組成變動 上海心瑋醫療科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈， 自2025年3月27日起，王國輝先生不再擔任董事會提名委員會（「提名委員會」） 成員，以加強本公司的企業管治，並履行將於2025年7月1日起實施的香港聯合 交易所有限公司證券上市規則（「上市規則」）有關提名委員會性別多元化的新 規定。張坤女士（「張女士」）已同時獲委任為提名委員會成員。緊隨變動後，提 名委員會將由兩名獨立非執行董事及一名執行董事，即馮向前先生（主席）、郭 少牧先生及張坤女士組成。 ...

Financial Performance - The company reported a revenue of RMB 277.9 million for the fiscal year ending December 31, 2024, representing a year-on-year growth of 19.6%[4] - Gross profit was RMB 181.7 million, with a gross margin of 65.4%, down from 70.5% in the previous year, reflecting a decrease of 5.1 percentage points[3] - The company significantly reduced its pre-tax loss to RMB 12.0 million, an 88.3% improvement compared to a loss of RMB 102.9 million in 2023[4] - The company reported a net loss attributable to equity holders of RMB 13.6 million, significantly reduced from RMB 94.0 million in the previous year, with a basic and diluted loss per share of RMB 0.36 compared to RMB 2.47[6] - Total revenue for 2024 reached RMB 277,899 thousand, an increase of 19.6% compared to RMB 232,344 thousand in 2023[19] - Revenue from medical device sales was RMB 276,931 thousand in 2024, up from RMB 232,344 thousand in 2023, reflecting a growth of 19.2%[19] - Revenue from service provision amounted to RMB 968 thousand in 2024, with no revenue reported in 2023[19] - Revenue from the mainland China market was RMB 269,504 thousand in 2024, compared to RMB 231,273 thousand in 2023, indicating a growth of 16.5%[19] - Other income totaled RMB 17,559 thousand in 2024, down from RMB 22,406 thousand in 2023, representing a decrease of 21.8%[21] - Government subsidies received were RMB 8,793 thousand in 2024, a decrease from RMB 11,211 thousand in 2023, reflecting a decline of 21.5%[21] Cost Management - Research and development costs were RMB 58.9 million, a decrease of 52.4% from RMB 123.8 million in the previous year, indicating effective cost control[3] - Sales and distribution expenses decreased by 10.4% to RMB 137.8 million, contributing to a lower expense ratio of 49.6% compared to 66.2% in 2023[4] - Administrative expenses decreased from RMB 74.6 million for the year ended December 31, 2023, to RMB 58.2 million for the year ending December 31, 2024, primarily due to a reduction in professional service fees[62] - Financial costs decreased from RMB 2.2 million for the year ended December 31, 2023, to RMB 1.7 million for the year ending December 31, 2024[65] Product Development and Market Strategy - The company achieved a 45.5% increase in sales of acute ischemic stroke treatment devices, with hemorrhagic stroke treatment devices and other interventional devices growing by 104.2% and 109.4%, respectively[4] - The company plans to launch at least two major neurointerventional devices in the next 24 months to address the growing demand for stroke treatment in the aging Chinese market[5] - The company has obtained CE or FDA certifications for several products and is currently registering over 40 products in 10 countries, laying the groundwork for long-term overseas sales goals[5] - The company aims to enhance its brand recognition as a comprehensive provider of neurointerventional devices and accelerate the commercialization of its pipeline products[53] - The company is focused on developing innovative medical devices in high-growth potential markets to create a competitive product portfolio beyond its neurointerventional business[53] Financial Stability - Total assets decreased to RMB 1,106.3 million in 2024 from RMB 1,141.5 million in 2023, while total liabilities also decreased, indicating improved financial stability[8] - The total trade receivables increased to RMB 97,381,000 in 2024 from RMB 78,659,000 in 2023, with an expected credit loss of RMB 2,668,000, representing a credit loss rate of 2.74%[28][31] - The company recognized a cumulative tax loss of RMB 686,522,000 as of December 31, 2024, which can be utilized to offset future taxable profits over the next 2 to 10 years[25] - The company has been granted a preferential income tax rate of 15% as a high-tech enterprise, applicable for the years ending December 31, 2023, and December 31, 2024[24] - The company has no supplier financing arrangements, thus recent accounting standard revisions will not impact its financial statements[14] - The company expects no significant impact on its financial performance or position from newly issued accounting standards in the foreseeable future[16] Corporate Governance - The company has adopted the corporate governance code to enhance management standards and protect shareholder interests[84] - The audit committee consists of three members, including two independent non-executive directors, ensuring compliance with listing rules[86] - The company confirms that all directors and supervisors have adhered to the standard code during the reporting period[85] - The company’s consolidated financial statements for the reporting period have been audited and comply with relevant accounting standards[87] - The chairman and CEO roles are held by the same individual, which deviates from the corporate governance code, but the board believes it enhances leadership effectiveness[84] Shareholder Returns - The company did not declare or pay any dividends during the year, consistent with the previous year[26] - The board does not recommend the payment of a final dividend for the reporting period, consistent with the previous year[81] Future Outlook - The company plans to apply for A-share listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board[54] - The company plans to hold its annual general meeting on May 26, 2025[89] - The company’s shares are listed on the Hong Kong Stock Exchange under the stock code 6609[89]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 董事會召開日期 上海心瑋醫療科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此 宣佈，本公司將於2025年3月27日（星期四）舉行董事會會議，藉以（其中包括） 審議及批准本公司及其附屬公司截至2024年12月31日止年度之全年業績及其發 佈，以及考慮建議派付末期股息（如有）。 承董事會命 上海心瑋醫療科技股份有限公司 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 董事長 王國輝 上海，2025年3月17日 於本公告日期，執行董事為王國輝先生、張坤女士及韋家威先生；非執行董事為丁魁先生、 陳少雄先生及陳剛先生；及獨立非執行董事為郭少牧先生、馮向前先生及龔平先生 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 根據上市規則第13.51B(2)條及第13.51(2)條作出的公告 王國輝 上海，2025年3月6日 於本公告日期，執行董事為王國輝先生、張坤女士及韋家威先生；非執行董事為丁魁先生、 陳少雄先生及陳剛先生；及獨立非執行董事為郭少牧先生、馮向前先生及龔平先生。 茲提述聯交所於2025年3月6日發佈的監管公告（「監管公告」），內容有關針對花 樣年、彩生活服務集團有限公司（聯交所上市公司，股份代號：1778）以及兩間 公司的若干董事或前任董事（包括郭先生）的公開譴責。根據監管公告，聯交所 發現（其中包括），(i)花樣年違反上市規則第十 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 臨時股東大會及該等類別股東大會的出席情況 董事會欣然宣佈，本公司於2024年11月7日（星期四）上午十時正假座中國上海 市自由貿易試驗區臨港新片區正博路356號38幢2層心瑋廳先召開臨時股東大會， 並於臨時股東大會結束後隨即召開該等類別股東大會。 臨時股東大會及該等類別股東大會由董事會根據中華人民共和國公司法及組 織章程細則召開，由執行董事兼董事會主席王國輝先生主持。本公司全體董事 王國輝先生、張坤女士、韋家威先生、丁魁先生、陳少雄先生、陳剛先生、郭 少牧先生、馮向前先生及龔平先生均親身或以電子方式出席臨時股東大會及 該等類別股東大會。 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6 ...

Financial Performance - For the first half of 2024, the company reported revenue of RMB 128.5 million, representing a year-on-year increase of 17.2%[6] - Gross profit was RMB 82.3 million, with a gross margin of 64.0%, down 8.7 percentage points compared to the same period last year[6] - The company narrowed its pre-tax loss to RMB 3.2 million, a 94.1% improvement year-on-year[6] - Revenue increased by 17.2% from RMB 109.6 million for the six months ended June 30, 2023, to RMB 128.5 million for the six months ended June 30, 2024, driven by sales growth in acute ischemic stroke devices and intracranial artery stenosis treatment devices[19] - Gross profit rose from RMB 79.7 million to RMB 82.3 million, but gross margin decreased from 72.7% to 64.0% due to price pressures from volume-based procurement and market competition[21] - The net loss for the six months ended June 30, 2024, was RMB 5,119 thousand, significantly reduced from a net loss of RMB 54,338 thousand in 2023[69] - Basic and diluted loss per share improved to RMB (0.14) from RMB (1.42) year-over-year[69] Research and Development - The company invested RMB 31.8 million in R&D, focusing on diversifying neuro-interventional devices[7] - Research and development costs decreased significantly from RMB 69.9 million to RMB 31.8 million, attributed to reduced raw material costs and a decrease in the number of R&D personnel[23] - The company is focusing on R&D and has incurred RMB 31,752 thousand in R&D expenses for the six months ended June 30, 2024[69] - Research and development expenses increased by 30% to RMB 200 million, focusing on innovative medical technologies[109] Product Development and Market Expansion - Neuro-interventional devices contributed 35.6% of total sales, generating revenue of RMB 45.8 million[7] - The company plans to launch at least five major neuro-interventional devices in the next 18 months, including innovative drug-eluting balloon catheters and self-expanding drug stents[7] - The intracranial drug-eluting balloon catheter is in the NMPA registration phase after completing clinical trials[11] - The company is evaluating opportunities for expanding the Captor product's indications and potential overseas marketing[10] - The company plans to enhance brand awareness as a comprehensive provider of neuro-interventional devices and expand sales of commercialized products[17] - The company aims to develop innovative medical devices in emerging treatment areas to create a competitive product portfolio beyond its neuro-interventional business[17] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[109] - A strategic acquisition of a local competitor is anticipated to enhance the company's product offerings and market reach[109] Regulatory and Compliance - The company has obtained CE or FDA certification for several products and is expanding its registration efforts in over ten other countries[7] - The company has 29 medical device products approved by NMPA, 3 products approved by FDA, and 1 product with CE mark as of the mid-term report date[6] - The company has adopted a code of conduct for trading its securities, confirming compliance by all directors and supervisors during the six months ended June 30, 2024[55] - The company has adhered to the corporate governance code, with all provisions complied with during the six months ended June 30, 2024, except for one[56] - The independent auditor, Ernst & Young, reviewed the group's interim financial data for the same period, ensuring accuracy and compliance[58] Shareholder Information and Incentive Plans - The 2021 H-share incentive plan was adopted on November 1, 2021, and has a validity period of ten years, with approximately 7.5 years remaining[41] - A total of 3,000,000 H-shares are allocated for three-year rewards, with a maximum of 30% vesting in the first year[43] - The plan is designed to align the interests of the leadership with those of shareholders and the overall group[38] - The company continues to implement its 2021 H-share incentive plan to align management interests with shareholder value[62] - The total number of shares available for the 2021 H-share incentive plan is 3,000,000, accounting for approximately 9.5% and 7.7% of the company's total H-share and issued share capital as of the report date[48] Cash Flow and Financial Position - Cash and bank balances as of June 30, 2024, were RMB 613.3 million, a decrease of RMB 8.9 million from RMB 622.2 million as of December 31, 2023[28] - The company reported a net cash flow from operating activities of RMB 8,799 thousand, a significant improvement from a net outflow of RMB 70,167 thousand in the same period of 2023[73] - The company reported an increase in cash and cash equivalents, totaling RMB 613,346 thousand at the end of the period, up from RMB 676,005 thousand in the previous year[74] - The company’s total cash and cash equivalents at the beginning of the period were RMB 605,583 thousand, with a net effect of exchange rate changes of RMB 454 thousand[74] Corporate Governance - The board consists of three non-executive directors, three independent non-executive directors, and three executive directors, ensuring a high level of independence[58] - The company plans to continue reviewing and monitoring its corporate governance standards to maintain high standards[58] - The audit committee, comprising independent non-executive directors, has reviewed the accounting principles and practices adopted by the group[58] - The company emphasizes the importance of internal controls and risk management in its financial reporting processes[58] Market Performance and User Engagement - User data showed an increase in active users by 15%, reaching a total of 3 million active users by June 30, 2024[109] - The company expects revenue growth to continue at a rate of 20% for the second half of 2024, driven by new product launches and market expansion[109] - Gross margin improved to 60%, up from 55% in the previous year, due to cost optimization strategies[109] - The company has launched two new products in Q2 2024, contributing to a 5% increase in overall sales[109]

Financial Performance - The company reported revenue of RMB 128.5 million for the first half of 2024, representing a year-on-year increase of 17.2%[2]. - Gross profit was RMB 82.3 million, with a gross margin of 64.0%, down 8.7 percentage points compared to the same period in 2023[2][3]. - The company narrowed its pre-tax loss to RMB 3.2 million, a decrease of 94.1% year-on-year[2][3]. - Revenue from customer contracts for the six months ended June 30, 2024, was RMB 128,484,000, an increase of 17.2% compared to RMB 109,586,000 for the same period in 2023[15]. - Revenue from medical device sales contributed RMB 128,484,000, with RMB 125,081,000 coming from mainland China, reflecting a growth from RMB 109,269,000 in the previous year[15]. - Other income for the six months ended June 30, 2024, totaled RMB 9,036,000, a decrease from RMB 10,746,000 in the same period of 2023[16]. - Interest income decreased to RMB 4,349,000 from RMB 6,433,000 year-over-year[16]. - Gross profit increased from RMB 79.7 million for the six months ended June 30, 2023, to RMB 82.3 million for the six months ended June 30, 2024, while gross margin decreased from 72.7% to 64.0% due to price impacts from volume-based procurement and market competition[36]. Research and Development - Research and development costs amounted to RMB 31.8 million, significantly reduced by 54.5% compared to the previous year[2][3]. - R&D expenses significantly decreased from RMB 69.9 million to RMB 31.8 million, attributed to reduced raw materials and consumables, a decrease in R&D team size, and lower third-party contracting costs[38]. - The company expects to launch at least five major neuro-interventional devices in the next 18 months, including innovative drug-eluting balloon catheters and self-expanding drug stents[3]. - The intracranial drug-eluting balloon catheter is in the NMPA registration phase after completing clinical trials, aimed at preventing vascular occlusion[27]. Sales and Distribution - Neuro-interventional devices contributed 35.6% of total sales, generating revenue of RMB 45.8 million[3]. - Sales from neurointerventional devices contributed 35.6% of total revenue, amounting to RMB 45.8 million[23]. - The sales of neurointerventional access devices and other products grew by 42.1% year-on-year to RMB 82.7 million[23]. - The company has established a distribution network covering over 2,000 hospitals across all provinces in China, excluding Hong Kong and Macau[30]. Financial Position - Total assets amounted to RMB 1,133.8 million, with net assets of RMB 1,069.98 million[6]. - Inventory increased to RMB 150.5 million, while trade receivables rose to RMB 85.0 million as of June 30, 2024[5]. - Trade receivables as of June 30, 2024, were RMB 85.0 million, compared to RMB 76.9 million as of December 31, 2023[21]. - Trade payables increased to RMB 5.7 million as of June 30, 2024, from RMB 3.7 million as of December 31, 2023[22]. - As of June 30, 2024, the company had no outstanding borrowings, and the debt-to-equity ratio remained stable at 3.4%[43]. - Cash and bank balances as of June 30, 2024, were RMB 613.3 million, a decrease of RMB 8.9 million from RMB 622.2 million as of December 31, 2023[44]. Corporate Governance - The company has adopted the corporate governance code to enhance management standards and protect shareholder interests[55]. - The audit committee consists of three members, including two independent non-executive directors, ensuring compliance with listing rules[56]. - The independent auditor has reviewed the group's interim financial data for the six months ending June 30, 2024[57]. - The board of directors is composed of three non-executive directors, three independent non-executive directors, and three executive directors, ensuring a high level of independence[55]. - The company emphasizes the importance of separating the roles of chairman and CEO, although both roles are currently held by the same individual[55]. - The company is committed to continuously reviewing and monitoring its corporate governance practices[55]. Future Plans - Plans to apply for A-share listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board to support future growth[32]. - The company aims to enhance its brand recognition as a comprehensive provider of neurointerventional devices and expand sales of commercialized products[32]. - The company is evaluating opportunities for overseas marketing of the Captor® device and may apply for registration in the United States[25].